AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19779321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 500 mg once daily
Number of subjects: 48
Study 19779321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine (UK-453,061) 750 mg once daily
Number of subjects: 48
Study 19779321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17481461 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Under Pressure (PUP) program
Number of subjects: 64
Study 17481461 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention control group (two-session parenting education intervention)
Number of subjects: 64
Study 17481461 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 64
Study 15900307 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplement (30 g soy protein, 9 g cotyledon fibre, 100 mg isoflavones)
Number of subjects: 100
Study 15900307 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplement
Number of subjects: 100
Study 15900307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 g of casein)
Number of subjects: 100
Study 15900307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12802453 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with larifan, ridostin, and viferon for 1 month
Number of subjects: 0
Study 12802453 — intervention group
Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 0
Study 9796889 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg orally twice daily
Number of subjects: 26
Study 9796889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8594665 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets
Number of subjects: 2300
Study 8594665 — intervention group
Group type: COMPARATOR
Intervention: Untreated bed nets
Number of subjects: 2300
Study 2569999 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 24
Study 2569999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 952692 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 units of oxytocin i.v.
Number of subjects: 148
Study 952692 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ergometrine i.v.
Number of subjects: 148
Study 30976339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (200 mcg every four hours up to four doses)
Number of subjects: 100
Study 30976339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol (200 mcg every four hours up to four doses)
Number of subjects: 100
Study 27965180 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting plus community health worker support
Number of subjects: 0
Study 27965180 — intervention group
Group type: COMPARATOR
Intervention: Goal-setting alone
Number of subjects: 0
Study 25979197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHG/70% IPA
Number of subjects: 100
Study 25979197 — intervention group
Group type: COMPARATOR
Intervention: 0.5% CHG/70% IPA
Number of subjects: 100
Study 23477506 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement for 8 weeks
Number of subjects: 70
Study 23477506 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 70
Study 21566054 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 731
Study 18187561 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 658
Study 18187561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 17225012 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative solar UV irradiation
Number of subjects: 0
Study 17225012 — intervention group
Group type: COMPARATOR
Intervention: No UV exposure (Control)
Number of subjects: 0
Study 15163340 — intervention group
Group type: EXPERIMENTAL
Intervention: T4/T3 combination therapy (5% of T4 dose substituted by T3)
Number of subjects: 23
Study 15163340 — intervention group
Group type: COMPARATOR
Intervention: T4 monotherapy
Number of subjects: 23
Study 15163340 — intervention group
Group type: EXPERIMENTAL
Intervention: T4/T3 combination therapy
Number of subjects: 23
Study 11339447 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (Group A)
Number of subjects: 20
Study 11339447 — intervention group
Group type: COMPARATOR
Intervention: Standard thoracotomy (Group B)
Number of subjects: 20
Study 8989173 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 108
Study 8989173 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 108
Study 8433182 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intervention including consultation for employers on nonsmoking policy, training for nonsmokers to assist smokers, and cessation classes for smokers.
Number of subjects: 8
Study 8433182 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-worker support for quitting in the intervention group.
Number of subjects: 8
Study 8433182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation among smokers whose co-workers frequently asked them not to smoke.
Number of subjects: 8
Study 3318461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (Dil)
Number of subjects: 22
Study 29540324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic approach (genotyping of ABCB1, CYP2C19*2, and CYP2C19*17)
Number of subjects: 888
Study 29540324 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (clinical characteristics alone)
Number of subjects: 888
Study 29540324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic arm (ticagrelor usage)
Number of subjects: 888
Study 29540324 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care arm (clopidogrel usage)
Number of subjects: 888
Study 29540324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (primary composite endpoint)
Number of subjects: 888
Study 27042193 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 169
Study 27042193 — intervention group
Group type: COMPARATOR
Intervention: Enfuvirtide (ENF)
Number of subjects: 169
Study 27042193 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of grade 2 or more LEE
Number of subjects: 169
Study 27042193 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir use
Number of subjects: 169
Study 27042193 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ALT at baseline
Number of subjects: 169
Study 25399892 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 11
Study 25399892 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 11
Study 23608085 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: ropivacaine, epinephrine, ketorolac, and clonidine
Number of subjects: 160
Study 23608085 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: ropivacaine, epinephrine, and ketorolac
Number of subjects: 160
Study 23608085 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: ropivacaine, epinephrine, and clonidine
Number of subjects: 160
Study 23608085 — intervention group
Group type: COMPARATOR
Intervention: Group D: ropivacaine and epinephrine
Number of subjects: 160
Study 20466363 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg conjugated estrogens orally for 7 days
Number of subjects: 24
Study 20466363 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g conjugated estrogens vaginally for 7 days
Number of subjects: 24
Study 17694376 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26
Study 17694376 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 26
Study 16650242 — intervention group
Group type: EXPERIMENTAL
Intervention: 5Fr catheter
Number of subjects: 200
Study 16650242 — intervention group
Group type: COMPARATOR
Intervention: 6Fr catheter
Number of subjects: 200
Study 12957559 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intervention group (n=10)
Number of subjects: 29
Study 12957559 — intervention group
Group type: COMPARATOR
Intervention: Baseline control group (n=8)
Number of subjects: 29
Study 12957559 — intervention group
Group type: COMPARATOR
Intervention: 3-month control group (n=11)
Number of subjects: 29
Study 11095657 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration
Number of subjects: 0
Study 11095657 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis
Number of subjects: 0
Study 9123711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose yohimbine hydrochloride (36 mg per day orally)
Number of subjects: 29
Study 9123711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8375223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g)
Number of subjects: 196
Study 8375223 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/Metronidazole (GM)
Number of subjects: 196
Study 3788500 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin‐dihydergot
Number of subjects: 181
Study 3788500 — intervention group
Group type: COMPARATOR
Intervention: heparin‐acenocoumarin
Number of subjects: 181
Study 29921153 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) group (n = 325)
Number of subjects: 615
Study 29921153 — intervention group
Group type: COMPARATOR
Intervention: No metabolic syndrome group (n = 290)
Number of subjects: 615
Study 29413356 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g/day of prescription omega‐3 fatty acids (P‐OM3) for 16 weeks
Number of subjects: 31
Study 29413356 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 31
Study 27095306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg once daily
Number of subjects: 190
Study 27095306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg once daily
Number of subjects: 190
Study 27095306 — intervention group
Group type: COMPARATOR
Intervention: Sonidegib (various doses from 100 to 3000 mg once daily and 250 to 750 mg twice daily)
Number of subjects: 190
Study 27095306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib (200 mg or 800 mg doses)
Number of subjects: 190
Study 24885374 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal magnetic resonance imaging (MRI) protocol and cognitive assessment
Number of subjects: 800
Study 24885374 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI brain scan, detailed clinical and cognitive assessment, blood and buccal mucosal samples
Number of subjects: 800
Study 22281018 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of anastrozole (1 mg)
Number of subjects: 24
Study 22281018 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of anastrozole (1 mg)
Number of subjects: 24
Study 20498181 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg THC twice daily
Number of subjects: 27
Study 20498181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18365856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (1 mg estradiol + 0.125 mg trimegestone)
Number of subjects: 0
Study 18365856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal hormone replacement therapy (150 or 300 microg estradiol + 200 mg micronized progesterone)
Number of subjects: 0
Study 18365856 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated computer-based analysis
Number of subjects: 0
Study 15762015 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine alone or in combination with donepezil
Number of subjects: 656
Study 15762015 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 656
Study 12088976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg IV pretreatment with fiberoptic intubation
Number of subjects: 100
Study 12088976 — intervention group
Group type: COMPARATOR
Intervention: Conventional orotracheal intubation without fentanyl
Number of subjects: 100
Study 12088976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg IV pretreatment with conventional laryngoscopy
Number of subjects: 100
Study 12088976 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic intubation without fentanyl
Number of subjects: 100
Study 9536660 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) in three divided doses
Number of subjects: 0
Study 9536660 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate (400 mg)
Number of subjects: 0
Study 9536660 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (200 mg)
Number of subjects: 0
Study 8703646 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 9
Study 8703646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength measured using a dynamometer (Bourdon tube)
Number of subjects: 122
Study 3338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed measured over 100 m
Number of subjects: 122
Study 3338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure activity assessed by questionnaire
Number of subjects: 122
Study 3338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between strength and walking speed
Number of subjects: 122
Study 3338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between strength and amount of walking (daily steps)
Number of subjects: 122
Study 3338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 122
Study 3338255 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily activity
Number of subjects: 122
Study 29914843 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Enterography (MRE)
Number of subjects: 284
Study 29914843 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 284
Study 28915900 — intervention group
Group type: EXPERIMENTAL
Intervention: α-GalCer-pulsed dendritic cell therapy
Number of subjects: 56
Study 28915900 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus vinorelbine (standard treatment)
Number of subjects: 56
Study 26403745 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOF (lipid emulsion formulation containing soybean oil, medium chain triglycerides, olive oil, and fish oil)
Number of subjects: 72
Study 26403745 — intervention group
Group type: COMPARATOR
Intervention: Medium or long chain lipid emulsion (control)
Number of subjects: 72
Study 23497590 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 500
Study 23497590 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral glucocorticoid dosing
Number of subjects: 500
Study 23497590 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced oral glucocorticoid dosing
Number of subjects: 500
Study 23497590 — intervention group
Group type: COMPARATOR
Intervention: No plasma exchange
Number of subjects: 500
Study 20814963 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of visual objects in a semantic classification task
Number of subjects: 0
Study 20814963 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial presentation of object names in a separate session
Number of subjects: 0
Study 20814963 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 19919172 — intervention group
Group type: EXPERIMENTAL
Intervention: Around-the-clock (RTC) intervention group (n = 7)
Number of subjects: 13
Study 19919172 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG) of controls (n = 6)
Number of subjects: 13
Study 19919172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study 17415017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (20, 30, or 50 mg once daily for 24 weeks)
Number of subjects: 71
Study 17415017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules once daily for 24 weeks)
Number of subjects: 71
Study 16279282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment (unopposed conjugated estrogens (CEE) 0.625 mg/day if without a uterus; CEE combined with medroxyprogesterone acetate (MPA) 2.5 mg/day otherwise)
Number of subjects: 2302
Study 16279282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2302
Study 11930740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia (freezing intercostal nerves for 1.5 minutes)
Number of subjects: 200
Study 11930740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryoanalgesia)
Number of subjects: 200
Study 11930740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 200
Study 11930740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia and Control
Number of subjects: 200
Study 9559497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthimus (High Tech Vision, Malmö, Sweden)
Number of subjects: 21
Study 9559497 — intervention group
Group type: COMPARATOR
Intervention: Humphrey (Humphrey Instruments Inc., San Leandro, CA, U.S.A.)
Number of subjects: 21
Study 7942668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with omeprazole 40 mg and amoxicillin
Number of subjects: 41
Study 7942668 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with omeprazole 40 mg, amoxicillin, and metronidazole
Number of subjects: 41
Study 7942668 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients with HP eradication
Number of subjects: 41
Study 7942668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with duodenal ulcers and HP eradication
Number of subjects: 41
Study 7942668 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 41
Study 3898514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% solution of epsilon aminocaproic acid (EACA)
Number of subjects: 75
Study 3898514 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus placebo
Number of subjects: 75
Study 30040755 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized scanning and mobility program (7 weeks, 3 times per week)
Number of subjects: 24
Study 30040755 — intervention group
Group type: COMPARATOR
Intervention: Individualized therapy recommended by clinicians
Number of subjects: 24
Study 27255923 — intervention group
Group type: COMPARATOR
Intervention: Existing program with monthly growth monitoring and nutritional/hygiene education (T0)
Number of subjects: 3750
Study 27255923 — intervention group
Group type: EXPERIMENTAL
Intervention: T0 + home visits for intensive nutrition counseling (T1)
Number of subjects: 3750
Study 27255923 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 + lipid-based supplementation (LNS) for children 6-18 months old (T2)
Number of subjects: 3750
Study 27255923 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 + LNS supplementation of pregnant/lactating women (T3)
Number of subjects: 3750
Study 27255923 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 + intensive home visiting program to support child development (T4)
Number of subjects: 3750
Study 24945932 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg single oral dose
Number of subjects: 0
Study 22187388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8-week program, 3 aerobic sessions per week)
Number of subjects: 38
Study 22187388 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 38
Study 20331739 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT) after immunochemotherapy
Number of subjects: 42
Study 20331739 — intervention group
Group type: COMPARATOR
Intervention: No involved-field radiotherapy (non-irradiated) after immunochemotherapy
Number of subjects: 42
Study 17805230 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (26+/‐5 g protein containing 44+/‐8 mg isoflavones per day)
Number of subjects: 34
Study 17805230 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (26+/‐5 g protein per day)
Number of subjects: 34
Study 17574730 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 0
Study 17574730 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 0
Study 14739037 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 80 mg/m2 on day 1; vindesine 3 mg/m2 on days 1 and 8: x3 courses)
Number of subjects: 119
Study 14739037 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (observation)
Number of subjects: 119
Study 10967379 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoid size (hypoplasia or absence)
Number of subjects: 36
Study 10967379 — intervention group
Group type: EXPERIMENTAL
Intervention: Early identification of adenoid absence or hypoplasia
Number of subjects: 36
Study 9131958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal and iliohipogastric nerve block (group A)
Number of subjects: 76
Study 9131958 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block (group B)
Number of subjects: 76
Study 9131958 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block (group C)
Number of subjects: 76
Study 9131958 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol intravenously (group D)
Number of subjects: 76
Study 8250359 — intervention group
Group type: EXPERIMENTAL
Intervention: carbonated 1% lignocaine (group 1)
Number of subjects: 60
Study 8250359 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (group 2)
Number of subjects: 60
Study 8250359 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 1 mixture of carbonated lignocaine and bupivacaine (group 3)
Number of subjects: 60
Study 8250359 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline added to lignocaine
Number of subjects: 60
Study 2951823 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent‐Berodual
Number of subjects: 10
Study 2951823 — intervention group
Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 10
Study 30857608 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular brachial plexus block
Number of subjects: 120
Study 30857608 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroclavicular brachial plexus block
Number of subjects: 120
Study 28275127 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) for 2 years
Number of subjects: 39